| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President, CEO, Chairman | EVP and Chief Strategy Officer
1 company
Lance Alstodt last filed a Form 4 in October 2025, as President, CEO, Chairman at BRTX. Lance Alstodt's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Lance Alstodt's trades have earned a middling insider score of 55/100 across 29 rated trades. Over a 12-month horizon, 37.9% of those trades were profitable, with an average 12-month return of -10.2%.
At the last filing, the largest reported position was 187,497 shares of BRTX. Net of sales, the BRTX filings show accumulation of 83,552 shares.
Lance Alstodt has 47 Form 4 filings on record from October 2018 to October 2025, all as President, CEO, Chairman at BioRestorative Therapies (BRTX), 2018–2025.
The 72 reported transactions were 50 open-market purchases, 11 option or other derivative awards, 4 dispositions back to the company and 3 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 33 purchases worth about $138K and no sales.
The largest open-market purchase was 4,500 shares of BRTX at an average $6.71 on November 16, 2021, about $30K. Twelve months later BRTX was down 56%.
Shares as reported in the last Form 4 for each company; the most recent is from October 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2023 | BRTX Biorestorative Therapies, Inc. | President, CEO, Chairman | Buy | 2,200 | $1.70 | $3,740.00 | +1.2% | +18.6% | +1.2% | |
| Sep 13, 2023 | BRTX Biorestorative Therapies, Inc. | President, CEO, Chairman | Buy | 800 | $1.53 | $1,226.00 | +0.4% | +22.7% | 0.0% | |
| Sep 6, 2023 | BRTX Biorestorative Therapies, Inc. | President, CEO, Chairman | Buy | 2,887 | $1.96 | $5,658.52 | +1.6% | -7.4% | -20.5% | |
| Jul 25, 2023 | BRTX Biorestorative Therapies, Inc. | President, CEO, Chairman | Buy | 4,200 | $2.44 | $10,248.00 | +2.3% | -22.2% | -29.6% | |
| Feb 1, 2023 | BRTX Biorestorative Therapies, Inc. | President, CEO, Chairman | Buy | 400 | $3.10 | $1,241.36 | +0.2% | +33.8% | -29.9% | |
| Jan 27, 2023 | BRTX Biorestorative Therapies, Inc. | President, CEO, Chairman | Buy | 200 | $3.01 | $602.00 | +0.1% | +35.9% | -47.5% | |
| Jan 20, 2023 | BRTX Biorestorative Therapies, Inc. | President, CEO, Chairman | Buy | 200 | $3.14 | $627.00 | +0.1% | +24.5% | -48.0% | |
| Jan 18, 2023 | BRTX Biorestorative Therapies, Inc. | President, CEO, Chairman | Buy | 400 | $3.11 | $1,244.30 | +0.2% | +13.7% | -47.9% | |
| Jan 9, 2023 | BRTX Biorestorative Therapies, Inc. | President, CEO, Chairman | Buy | 100 | $3.08 | $308.00 | - | +17.5% | -43.5% | |
| Dec 23, 2022 | BRTX Biorestorative Therapies, Inc. | President, CEO, Chairman | Buy | 300 | $3.01 | $903.00 | +0.2% | +6.0% | -41.5% |